Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hogan

Showing results (1251-1260 of 1,303) with videos related to

Pageof 131
Sort By:
Mass Spectrometry Reviews|February 2, 2019
Recommendations for reporting ion mobility Mass Spectrometry measurementsValérie Gabelica, Alexandre A Shvartsburg, Carlos Afonso, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
American Journal of Human Genetics|December 1, 2014
Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathologyGabrielle R Wilson, Joe C H Sim, Catriona McLean, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 31, 2021
A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder WorkshopsSimon A Carter, Liz Lightstone, Dan Cattran, et al.
Kidney International|May 8, 2021
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular diseaseSimon A Carter, Charlotte Logeman, Martin Howell, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Cancer Journal|May 7, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Pageof 131

Showing results (1251-1260 of 1,303) with videos related to

Sort By:
Pageof 131
Mass Spectrometry Reviews|February 2, 2019
Recommendations for reporting ion mobility Mass Spectrometry measurementsValérie Gabelica, Alexandre A Shvartsburg, Carlos Afonso, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
American Journal of Human Genetics|December 1, 2014
Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathologyGabrielle R Wilson, Joe C H Sim, Catriona McLean, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 31, 2021
A Core Outcome Set for Trials in Glomerular Disease: A Report of the Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD) Stakeholder WorkshopsSimon A Carter, Liz Lightstone, Dan Cattran, et al.
Kidney International|May 8, 2021
Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular diseaseSimon A Carter, Charlotte Logeman, Martin Howell, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Cancer Journal|May 7, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohortMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Bone Marrow Transplantation|July 11, 2018
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statementWilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Pageof 131